Welcome to our dedicated page for Avidity Biosciences SEC filings (Ticker: RNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Avidity Biosciences, Inc. (Nasdaq: RNA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed insight into how Avidity describes its Antibody Oligonucleotide Conjugates (AOCs™) platform, its late-stage neuromuscular programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD), and its broader pipeline in precision cardiology and immunology.
Current reports on Form 8-K are especially important for tracking material events at Avidity. Recent 8-K filings have covered topics such as the definitive merger agreement with Novartis AG, the related Separation and Distribution Agreement for the spin-off or sale of early-stage precision cardiology programs into SpinCo, positive clinical data from the EXPLORE44® and EXPLORE44-OLE™ trials of delpacibart zotadirsen (del-zota) in DMD44, and regulatory milestones including Breakthrough Therapy designation and updated BLA submission timing for del-zota. Other 8-Ks detail public equity offerings, amendments to equity incentive plans, and executive compensation arrangements in connection with the proposed merger.
Investors and analysts can also use Avidity’s SEC filings to confirm listing information for its common stock (trading under the symbol RNA on The Nasdaq Global Market), review descriptions of SpinCo and the planned spin-off structure, and understand the conditions, termination provisions and timing expectations associated with the Novartis transaction. These filings often reference additional documents such as proxy statements, registration statements for SpinCo and financial reports that further explain Avidity’s operations, risk factors and capital structure.
On Stock Titan, Avidity’s filings are supplemented by AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify items such as clinical program updates, collaboration milestones, merger terms and changes in executive compensation. Real-time updates from EDGAR, combined with structured access to Forms 8-K and other filings, make this page a practical starting point for reviewing Avidity’s regulatory history, including material events related to its AOC platform, neuromuscular pipeline and the proposed acquisition by Novartis.
Avidity Biosciences (RNA) reported Q3 2025 results with collaboration revenue of $12,475k and operating expenses of $201,281k, leading to a net loss of $174,442k ($1.27 per share). Cash, cash equivalents and marketable securities totaled $1,875,836k as of September 30, 2025, supported by recent equity raises.
The company strengthened its balance sheet with an underwritten public offering of 17,250,000 shares for approximately $651.4 million in net proceeds and sold 5,646,583 shares via its ATM for $185.5 million. As of October 31, 2025, shares outstanding were 150,675,742.
Subsequent event: Avidity entered a definitive agreement to be acquired by Novartis for $72.00 per share in cash, alongside a planned spin-off of precision cardiology assets at a distribution ratio of 1 SpinCo share per 10 Avidity shares, funded with $270 million, subject to customary conditions. R&D programs advanced, including del-zota in DMD44 (Breakthrough Therapy) and ongoing pivotal studies in DM1 and FSHD. Commitments include a $621.6 million manufacturing agreement for 2026–2028 and new headquarters leases.
Avidity Biosciences (RNA) furnished quarterly results information via Form 8-K. The company reported that it issued a press release announcing financial results for the quarter ended September 30, 2025, and attached the release as Exhibit 99.1. The Item 2.02 information, including Exhibit 99.1, is provided under General Instruction B.2 and is not deemed filed for liability purposes under the Exchange Act.
Novartis filed definitive additional proxy materials regarding its proposed acquisition of Avidity Biosciences (RNA), outlining strategic rationale and next steps. CEO Vasant Narasimhan highlighted Avidity’s antibody-oligonucleotide conjugate platform, which pairs monoclonal antibodies with siRNA or antisense oligonucleotides to target tissues beyond the liver, with a focus on muscle for neuromuscular diseases.
The materials describe plans tied to Avidity’s programs in myotonic dystrophy (DM1), facioscapulohumeral muscular dystrophy (FSHD) and Duchenne muscular dystrophy (DMD). Novartis stated it raised guidance to 6% sales growth over the next five years and expects a core margin of 40%+ in 2029, and noted more investment given the potential acquisition. Avidity will file a preliminary and definitive proxy for a special meeting related to the Transactions, which also contemplate a spin-off or sale of SpinCo and a merger. The filing includes customary cautionary and solicitation disclosures.
Novartis AG filed a DFAN14A featuring an employee letter about its proposed acquisition of Avidity Biosciences (RNA) and a related spin-off or sale of SpinCo. The message highlights Avidity’s RNA therapeutics platform and late-stage programs in DM1, FSHD, and DMD, and notes that both companies will operate separately until closing.
Avidity will deliver a definitive proxy statement and proxy card to stockholders in advance of a special meeting to consider the transactions. The communication includes extensive forward‑looking statements and emphasizes conditions such as regulatory approvals and Avidity stockholder approval. It also outlines potential risks, including disruption from the transactions, execution of the SpinCo separation, competing proposals, and possible stockholder litigation.
Novartis AG filed definitive additional proxy materials (DFAN14A) under Rule 14a-12 regarding its proposed acquisition of Avidity Biosciences (RNA), which also contemplates a spin-off or sale of a subsidiary referred to as SpinCo. The materials include social media posts and an internal email dated October 27, 2025.
Avidity intends to file a preliminary and definitive proxy statement, and its stockholders will receive a definitive proxy statement and proxy card in advance of a special meeting to vote on the Transactions. Completion remains subject to customary closing conditions, including regulatory approvals and approval of Avidity’s stockholders. The communication emphasizes that it is not an offer to sell or solicit any security and includes forward-looking statements with outlined risks.
Avidity Biosciences (RNA) agreed to be acquired by Novartis for $72.00 per share in cash, with Avidity becoming an indirect wholly owned subsidiary after closing. The deal is conditioned on a pre-closing separation of early-stage precision cardiology assets into Bryce Therapeutics (SpinCo) and completion of either a pro rata Spin-Off or a permitted sale of SpinCo.
Spin-Off terms: stockholders are to receive 1 share of SpinCo Common Stock for every 10 Avidity shares; SpinCo is to be funded with $270 million (net of SpinCo’s existing cash, cash equivalents and marketable securities) and is intended to list on Nasdaq. Equity awards are to be cashed out at $72 per underlying share at closing, with holders as of the Spin-Off record date also entitled to the 1-for-10 SpinCo distribution. Warrants will receive the merger consideration and may receive cash from any permitted sale proceeds pursuant to their terms.
Conditions and timing: closing requires effectiveness of the Spin-Off registration, completion of the Spin-Off or permitted sale, HSR clearance, other specified antitrust clearances, absence of legal restraints, no Company Material Adverse Effect, and majority stockholder approval. The parties expect closing in the first half of 2026. The Outside Date is July 27, 2026, extendable to October 26, 2026 in specified circumstances. The agreement includes a $450 million termination fee and a $600 million reverse termination fee. The Merger and Spin-Off are expected to be taxable to stockholders.
Novartis AG filed additional proxy solicitation materials related to its planned acquisition of Avidity Biosciences (RNA), alongside a proposed spin-off or sale of SpinCo. The materials note that Avidity will file a preliminary and definitive proxy statement, and that completion remains subject to customary conditions, including regulatory clearances and approval of Avidity’s stockholders.
The content includes a media report that Novartis agreed to buy Avidity for $12bn, or $72 per share, a 46% premium to the prior close, with an enterprise value of $11bn. The report also states Avidity will spin off its cardiovascular programs and that Novartis expects the deal to lift its 2024–2029 CAGR from 5% to 6% while diluting profitability by 1–2 percentage points, without changing this year’s guidance. Disclosures emphasize forward-looking risks and instruct Avidity stockholders to read the definitive proxy statement when available.
Avidity Biosciences (RNA) reported insider activity by its Chief Medical Officer. On October 22, 2025, the officer exercised a stock option for 2,209 shares at $10.16 and sold 2,209 shares at a weighted-average price of $47.5394, executed under a Rule 10b5-1 trading plan adopted on June 12, 2024.
Following these transactions, the officer held 38,867 shares of common stock directly and 68,458 derivative securities (stock options). The referenced option was granted on January 20, 2024 and vests in equal monthly installments of 2,208 shares until fully vested and exercisable on January 20, 2028.
Avidity Biosciences (RNA)10/15/2025, the officer exercised 20,000 stock options at an exercise price of $22.34 and sold 20,000 shares at a weighted-average price of $50.1529 under a Rule 10b5-1 trading plan adopted on April 11, 2025. Following the transactions, the officer directly held 97,130 shares. The filing notes a remaining 65,000 derivative securities (options). The sale price reflected multiple trades between $48.20 and $51.19.
FAQ
What is the current stock price of Avidity Biosciences (RNA)?
What is the market cap of Avidity Biosciences (RNA)?
